Canada markets close in 2 hours 36 minutes

Biofrontera Inc. (BFRI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9706+0.0942 (+10.75%)
As of 01:23PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.8764
Open0.8928
Bid0.9705 x 1400
Ask0.9800 x 1800
Day's Range0.8799 - 1.0400
52 Week Range0.8600 - 14.6300
Volume366,133
Avg. Volume759,222
Market Cap22.859M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.5900
Earnings DateApr 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Simply Wall St.

    Here's Why Biofrontera (NASDAQ:BFRI) Must Use Its Cash Wisely

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

  • GlobeNewswire

    Biofrontera Inc.’s Marketing Campaign and Website for Ameluz Won 2022 PM360 Trailblazer Awards

    WOBURN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that PM360, a publication for marketing decision makers in the pharmaceutical, biotech, diagnostics and medical device industries, has awarded the previously nominated Ameluz® marketing campaign, created by Biofrontera Inc. along with Elevate Healthcare, “Relaunch/Revitalization of the Year” and “Professio

  • GlobeNewswire

    Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director

    WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Gerard DiGirolamo as National Sales Director. In this newly created position, Mr. DiGirolamo will report to Mark Baldyga, Biofrontera’s Head of Sales & Marketing, and will help execute the Company’s U.S. sales division and objectives including the strategic design, expansion and leadership of